Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
- Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
June 6, 2023
- Japan Likely to Approve Its 1st Cold Meds Containing Loxoprofen
June 6, 2023
- LDP Project Team Submits Proposal to Prime Minister
June 5, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
- Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
- Ferring’s Oral Budesonide for UC Passes Advisor Review for Approval
June 5, 2023
- Deregulation Panel Urges Discussions on Secondary Use of Medical Data Without Patient Consent
June 2, 2023
- Public Knowledge-Based Application OK’ed for Endoxan Label Expansion
June 2, 2023
- SaMD Could Be Eligible for 2-Stage Approval System: MHLW
June 1, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan to Quadruple Supplies of Sublingual Hay Fever Therapy in 5 Years
May 31, 2023
- LDP OKs Project Team Proposal to Boost Pharma Innovation, Create Command Tower
May 31, 2023
- LDP Launches Lawmakers’ League on Self-Medication
May 31, 2023
- Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
- Japan Trade Minister Demands China Release Detained Astellas Employee
May 30, 2023
- MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
- Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Clear Review for June Approval
May 30, 2023
- PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…